Education/ACR/EULAR

Making Methotrexate More Effective Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p

Links:

Dr. John Cush @RheumNow( View Tweet )
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Links:

Dr. John Cush @RheumNow( View Tweet )
Treat to Target Works in Elderly Onset RA Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP

Links:

Dr. John Cush @RheumNow( View Tweet )
Digital Platforms and AI Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions. https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf

Links:

Dr. John Cush @RheumNow( View Tweet )
Digital Patient Education in RA Dr. Bella Mehta reviews abstract OP005-HPR presented in London at EULAR 2026 https://t.co/Wj8omKJTNx. https://t.co/h13p54BAHs

Links:

Dr. John Cush @RheumNow( View Tweet )
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.

Dr. John Cush @RheumNow( View Tweet )

Day 1 Report from EULAR 2026 The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush @RheumNow( View Tweet )
Who does better in active #RA b/tsDMARD naive? Pt choice TNFi or JAKi OR Pt randomized to TNFI or JAKi? Strangely or not PT choice did better ✅with satisfaction ~maybe expected ✅better retention on chosen #Rx 🤔unexpected another arm in #RCTS?” #EULAR2026 @RheumNow OP0204 https://t.co/7qx5Rqq6a7

Links:

Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃 https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush @RheumNow( View Tweet )

@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts https://t.co/smN8hg51nj

Links:

Jiha Lee @JihaRheum( View Tweet )

🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow https://t.co/IhGQSxssyd

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and

Read Article
Some new #vaccination #recommendations #EULAR2026 @RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86

Links:

Janet Pope @Janetbirdope( View Tweet )
Remember Babies of pts on chronic #immunosuppression with #SARDs ❎delay #vaccinations til 6/12 For safety & to mount sufficient response #rotovirus #vaccine is Ok before 6 months or vaccine is ineffective Pts w #SARDs need #COVID shots @RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY

Links:

Janet Pope @Janetbirdope( View Tweet )
What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

Links:

sheila @RHEUMarampa( View Tweet )
#EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL

Links:

Janet Pope @Janetbirdope( View Tweet )
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246

Jiha Lee @JihaRheum( View Tweet )

Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults. "Steroids and Me" (Sam) provides online patient education ~5 minutes. @RheumNow #EULAR2026 POS1388

Jiha Lee @JihaRheum( View Tweet )

Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW

Links:

sheila @RHEUMarampa( View Tweet )
T2T works in elderly-onset #RA. tREACH trial (n=425): EORA (mean age 73) achieve LDA similar to young-onset RA; often with lower treatment intensity when seronegative. Drug tolerability comparable in EORA vs YORA despite more comorbidities. @RheumNow #EULAR2026 POS1326 https://t.co/tKRki2KLzP

Links:

Jiha Lee @JihaRheum( View Tweet )
Checklist IgG4

INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease

Henrique Dalmolin, MD

B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.

Read Article
#EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practice, caught up with colleagues and formed new collaborations. Thank you @eular_org. Hope you enjoyed our @RheumNow coverage. See you in Berlin 🇩🇪 #EULAR2027 https://t.co/nyaBnHLrxr

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow

Nelly ZIADE 🍀 @Nellziade( View Tweet )

ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

Therapeutic Updates

Underserved and Under-treated

RheumNow
Lindsay Tom Pitfalls in OP
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs
Read Post

Recent Blogs

Advanced Practice Rheum

Safety of Biologics and Novel Agents

Jack Cush, MD
APR Safety Video Cover
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
Advanced Practice Rheum

Fibromyalgia

Jack Cush, MD
APR fibro video cover
Dr. Jack Cush reviews fibromyalgia.
Read Article
Advanced Practice Rheum

Steroids

Jack Cush, MD
STEROIDS COVER
In this Advanced Practice Rheum, Dr. Jack Cush reviews steroids.
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • Day 4 Recap EULAR 2026
  • ACR 2025 Daily Podcasts Day4b
  • ACR 2025 Daily Podcasts Day4a
×